These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19627632)

  • 21. Plasmodium falciparum malaria in the Peruvian Amazon, a region of low transmission, is associated with immunologic memory.
    Clark EH; Silva CJ; Weiss GE; Li S; Padilla C; Crompton PD; Hernandez JN; Branch OH
    Infect Immun; 2012 Apr; 80(4):1583-92. PubMed ID: 22252876
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay.
    Miura K; Zhou H; Diouf A; Moretz SE; Fay MP; Miller LH; Martin LB; Pierce MA; Ellis RD; Mullen GE; Long CA
    Clin Vaccine Immunol; 2009 Jul; 16(7):963-8. PubMed ID: 19439523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys.
    Kumar S; Yadava A; Keister DB; Tian JH; Ohl M; Perdue-Greenfield KA; Miller LH; Kaslow DC
    Mol Med; 1995 Mar; 1(3):325-32. PubMed ID: 8529111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibodies and Plasmodium falciparum merozoites.
    Ramasamy R; Ramasamy M; Yasawardena S
    Trends Parasitol; 2001 Apr; 17(4):194-7. PubMed ID: 11282510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Growth-inhibitory antibodies are not necessary for protective immunity to malaria infection.
    Murhandarwati EE; Wang L; de Silva HD; Ma C; Plebanski M; Black CG; Coppel RL
    Infect Immun; 2010 Feb; 78(2):680-7. PubMed ID: 19917716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein.
    Soe S; Theisen M; Roussilhon C; Aye KS; Druilhe P
    Infect Immun; 2004 Jan; 72(1):247-52. PubMed ID: 14688102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.
    Chitnis CE; Mukherjee P; Mehta S; Yazdani SS; Dhawan S; Shakri AR; Bhardwaj R; Gupta PK; Hans D; Mazumdar S; Singh B; Kumar S; Pandey G; Parulekar V; Imbault N; Shivyogi P; Godbole G; Mohan K; Leroy O; Singh K; Chauhan VS
    PLoS One; 2015; 10(4):e0117820. PubMed ID: 25927360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacies against Plasmodium chabaudi malaria based on prechallenge antibody responses.
    Lynch MM; Cernetich-Ott A; Weidanz WP; Burns JM
    Clin Vaccine Immunol; 2009 Mar; 16(3):293-302. PubMed ID: 19116303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis.
    Fowkes FJ; Richards JS; Simpson JA; Beeson JG
    PLoS Med; 2010 Jan; 7(1):e1000218. PubMed ID: 20098724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibodies that inhibit binding of Plasmodium falciparum-infected erythrocytes to chondroitin sulfate A and to the C terminus of merozoite surface protein 1 correlate with reduced placental malaria in Cameroonian women.
    Taylor DW; Zhou A; Marsillio LE; Thuita LW; Leke EB; Branch O; Gowda DC; Long C; Leke RF
    Infect Immun; 2004 Mar; 72(3):1603-7. PubMed ID: 14977967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biological activities of anti-merozoite surface protein-1 antibodies induced by adjuvant-assisted immunizations in mice with different immune gene knockouts.
    Hui G; Choe D; Hashimoto C
    Clin Vaccine Immunol; 2008 Aug; 15(8):1145-50. PubMed ID: 18562564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody levels to multiple malaria vaccine candidate antigens in relation to clinical malaria episodes in children in the Kasena-Nankana district of Northern Ghana.
    Dodoo D; Atuguba F; Bosomprah S; Ansah NA; Ansah P; Lamptey H; Egyir B; Oduro AR; Gyan B; Hodgson A; Koram KA
    Malar J; 2011 May; 10():108. PubMed ID: 21529376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative analysis of the profiles of IgG subclass-specific responses to Plasmodium falciparum apical membrane antigen-1 and merozoite surface protein-1 in naturally exposed individuals living in malaria hypoendemic settings, Iran.
    Rouhani M; Zakeri S; Mehrizi AA; Djadid ND
    Malar J; 2015 Feb; 14():58. PubMed ID: 25652589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acquisition of invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein 1 in a transmigrant population requires multiple infections.
    Murhandarwati EE; Black CG; Wang L; Weisman S; Koning-Ward TF; Baird JK; Tjitra E; Richie TL; Crabb BS; Coppel RL
    J Infect Dis; 2008 Oct; 198(8):1212-8. PubMed ID: 18717639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasmodium berghei circumvents immune responses induced by merozoite surface protein 1- and apical membrane antigen 1-based vaccines.
    Yoshida S; Nagumo H; Yokomine T; Araki H; Suzuki A; Matsuoka H
    PLoS One; 2010 Oct; 5(10):e13727. PubMed ID: 21060850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure.
    Biswas S; Choudhary P; Elias SC; Miura K; Milne KH; de Cassan SC; Collins KA; Halstead FD; Bliss CM; Ewer KJ; Osier FH; Hodgson SH; Duncan CJ; O'Hara GA; Long CA; Hill AV; Draper SJ
    PLoS One; 2014; 9(9):e107903. PubMed ID: 25254500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses.
    Lyon JA; Angov E; Fay MP; Sullivan JS; Girourd AS; Robinson SJ; Bergmann-Leitner ES; Duncan EH; Darko CA; Collins WE; Long CA; Barnwell JW
    PLoS One; 2008 Jul; 3(7):e2830. PubMed ID: 18665258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody profiles to plasmodium merozoite surface protein-1 in Cambodian adults during an active surveillance cohort with nested treatment study.
    Spring MD; Pichyangkul S; Lon C; Gosi P; Yongvanichit K; Srichairatanakul U; Limsalakpeth A; Chaisatit C; Chann S; Sriwichai S; Auayapon M; Chaorattanakawee S; Dutta S; Prom S; Meng Chour C; Walsh DS; Angov E; Saunders DL
    Malar J; 2016 Jan; 15():17. PubMed ID: 26747132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disulfide bonds in merozoite surface protein 1 of the malaria parasite impede efficient antigen processing and affect the in vivo antibody response.
    Hensmann M; Li C; Moss C; Lindo V; Greer F; Watts C; Ogun SA; Holder AA; Langhorne J
    Eur J Immunol; 2004 Mar; 34(3):639-648. PubMed ID: 14991593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MSP1(19) miniproteins can serve as targets for invasion inhibitory antibodies in Plasmodium falciparum provided they contain the correct domains for cell surface trafficking.
    Gilson PR; O'Donnell RA; Nebl T; Sanders PR; Wickham ME; McElwain TF; de Koning-Ward TF; Crabb BS
    Mol Microbiol; 2008 Apr; 68(1):124-38. PubMed ID: 18333885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.